Madrigal Pharmaceuticals (MDGL) Operating Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Operating Expenses data on file, last reported at $404.1 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 86.58% year-over-year to $404.1 million in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 823.54% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 20090.92% from the prior year.
• Operating Expenses for Q1 2026 stood at $404.1 million, down from $1.2 billion in the prior quarter.
• Over the last five years, Operating Expenses for MDGL reached as high as $1.2 billion in Q4 2025 and fell as low as -$501.5 million in Q4 2024.
• Historically, Operating Expenses has averaged $152.1 million across 5 years, with a median of $82.9 million in 2022.
• Across the five-year window, Operating Expenses tumbled 527.95% in 2024 and jumped 18545.12% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $85.3 million in 2022, then jumped by 37.37% to $117.2 million in 2023, then tumbled by 527.95% to -$501.5 million in 2024, then surged by 344.65% to $1.2 billion in 2025, then slumped by 67.06% to $404.1 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $404.1 million in Q1 2026, $1.2 billion in Q4 2025, and $401.2 million in Q3 2025.